Pass Co., Ltd.
“Fucoxanthin” Hokkaido Medical University research results Part 2! Paper published on anti-cancer effect on model mice!
……
Alnur Co., Ltd. (hereinafter referred to as Alnur), a consolidated subsidiary of Pass Co., Ltd. (Shibuya-ku, Tokyo, TSE Standard Market Code No. 3840), announced on June 27, 2022, “Fucoxanthin, Hokkaido Medical University Research Results 1st As announced in “Confirming the anticancer effect in model mice”, the results of research on “Colon cancer chemoprevention using microalgae-derived fucoxanthin” with the Faculty of Pharmacy, Hokkaido Medical University and the Institute of Traditional Chinese Medicine Co., Ltd. The anticancer effect of fucoxanthin derived from microalgae has been confirmed in colon carcinogenesis model mice.
Recently, the experimental results of administering fucoxanthin extracted and purified with Arnur to tumor-bearing model mice, which were provided to Associate Professor Masaru Terasaki of the Faculty of Pharmaceutical Sciences, Hokkaido Medical University, have been published in Cancer Genomics & Proteomics (hereinafter referred to as CGP). I would like to inform you that.
[Image 1
Research has shown that Alnur’s fucoxanthin has a clear anti-tumor effect on tumor tissues close to human colon cancer tissue, making this product one of the treatment candidates for human colon cancer in the future. There is a possibility. In the future, we would like to investigate the anticancer effects of this product in more detail. In addition, the CGP, where the paper will be published, is an
international anti-cancer research publication that aims to rapidly publish high-quality papers and reviews on the application of genomic and proteomic technologies to basic, experimental, and clinical cancer research. This is the media in which it is published.
■Paper details
Journal: Cancer Genomics & Proteomics
https://cgp.iiarjournals.org/
title
Fucoxanthin inhibits Development of Sigmoid Colorectal Cancer in a PDX Model with Alterations of Growth, Adhesion, and Cell Cycle Signals (Translation: Fucoxanthin alters proliferation, adhesion, and cell cycle signals and suppresses tumor growth in sigmoid colon cancer PDX model)
https://cgp.iiarjournals.org/content/20/6suppl/686
overview
Fucoxanthin (Fx) exhibits potent anticancer effects in various colorectal cancer (CRC) animal models. However, the therapeutic effects of Fx on human cancer tissues are unknown. Patient-derived xenograft (PDX) mouse models transplanted with patient-derived cancer tissue are widely accepted as the best preclinical model for evaluating the anticancer effects of drug candidates. In this study, we investigated the anticancer effects of Fx through proteome analysis using PDX mice (CRC-PDX) transplanted with cancer tissue derived from sigmoid colon cancer patients. As a result, when Fx was administered to CRC-PDX mice, tumor growth was significantly suppressed (0.6 times that of tumors in the control group), and a tendency to induce differentiation was observed. Furthermore, administration of Fx increased the expression of glycanated-DCN and decreased the expression of DSN1, pFAK (Tyr397), pPaxillin (Tyr31), and c-MYC in tumor tissues of CRC-PDX mice. These protein changes were consistent with protein changes in human CRC cells that were induced to undergo apoptosis by adding fucoxanthinol (a major metabolite of Fx in vivo). Therefore, it was considered that administration of Fx caused metabolites of Fx to directly act on tumor tissues of PDX mice, causing tumor growth inhibition.
These results suggested that Fx suppresses the proliferation of human-like CRC tissues, particularly through proliferation, adhesion, and cell cycle signals.
[Image 2
Note) This press release is an introduction to the paper and does not support the efficacy or safety of Alnur’s fucoxanthin against cancer. ■University overview
Name: Hokkaido Medical University Faculty of Pharmacy
Address: 1757 Kanazawa, Tobetsu-cho, Ishikari-gun, Hokkaido
Associate Professor Masaru Terasaki: He has been researching fucoxanthin for many years, and recently published “Anticancer Effects of Fucoxanthin in a PDX Model of Advanced Stage Pancreatic Cancer with Alteration of Several Multifunctional Molecules, Onco 2023, 3(4), 217-236” We have published academic papers.
[Published paper URL] https://www.mdpi.com/2673-7523/3/4/16
■About our consolidated subsidiaries
Company name: Alnur Co., Ltd. https://www.alnur.jp/
Head Office: JPR Harajuku Building, 6-17-11 Jingumae, Shibuya-ku, Tokyo R&D Center: 1-25-3 Takada, Toshima-ku, Tokyo
Representative: Representative Director Atsuyuki Hoshi
Founded: November 2020
Capital: 30,000,000 yen
Business Overview: Research, development, manufacturing and sales, import and export of related products and technologies in the biomedical and healthcare fields, with a focus on microalgae. ■About Pass Co., Ltd.
Company name: PATH corporation https://www.pathway.co.jp/index.html Tokyo Stock Exchange Standard Market Stock Code 3840 (Listed in March 2007) Head Office: JPR Harajuku Building, 6-17-11 Jingumae, Shibuya-ku, Tokyo Representative: Representative Director Yuzo Takahashi
Founded: September 1990
Capital: 1,052,405 thousand yen (as of September 30, 2023)
Business overview: Mail order business (beauty/health)
-Inquiries from the press-
Pass Co., Ltd. Management Headquarters Yumi Kosasa
TEL: 03-6823-6664
E-mail: info@pathway.co.jp